Study 903 Results: Development of Resistance Mutations through Week 48 (ITT)
1 K103N, V106M, Y188C/L or G190A/S/E/Q (K103N in 19/28; others > 50-fold EFV-R with other mutations); 3 patients (all in TDF arm) had > 4-fold EFV resistance at baseline and developed additional EFV resistance mutations
2 One patient additionally developed D67G + K70E + V75L associated with >20-fold 3TC resistance, but no tenofovir susceptibility change
3 One patient had K219Q at baseline, but did not develop any new mutations
4 In combination with K70R (6.1-fold d4T resistance)
| Previous slide | Next slide | Back to first slide | View graphic version |